contactin associated protein family member 3BGenealiases: []
Q-omics provides the consensus-scored CNTNAP3B profile across patient tissues and cancer cell-line models. CNTNAP3B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CNTNAP3B is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CNTNAP3B RNA expression shows 15,450 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where CNTNAP3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTNAP3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTNAP3B survival associations across molecular data types. CNTNAP3B RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTNAP3B RNA expression–survival associations across cancer types. High CNTNAP3B expression shows unfavorable associations in BLCA, ACC, KIRP and LGG, but favorable associations in KIRC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CNTNAP3B RNA expression.
This table summarizes CNTNAP3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CNTNAP3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTNAP3B shows lower tumor expression in KICH, LUAD, THCA, BRCA and KIRC and higher tumor expression in LIHC. The KICH box plot shows higher CNTNAP3B RNA expression in normal versus tumor tissue (log2 FC = −0.654, t-test p < 0.001).
This table shows molecular features associated with CNTNAP3B in patient tissues and cancer cell lines. In patient samples, CNTNAP3B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CNTNAP3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
